Evidence map›Paper›PMID 26233847›Full record

ArticleChinese journal of natural medicines2015

Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats.

Jun-Xian Yu, Sukesh Voruganti, Dan-Dan Li, Jiang-Jiang Qin, Subhasree Nag, Su Xu, Sadanandan E Velu, Wei Wang, Ruiwen Zhang

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese journal of natural medicines, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jun-Xian YuKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China; Center for Drug Evaluation, China Food and Drug Administration, Beijing 100038, China.
Sukesh VorugantiKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China; China Pharmaceutical University, Nanjing 210009, China.
Dan-Dan LiCenter for Drug Evaluation, China Food and Drug Administration, Beijing 100038, China.
Jiang-Jiang QinKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China; China Pharmaceutical University, Nanjing 210009, China.
Subhasree NagKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Su XuChina National Institutes for Food and Drug Control, Beijing 100035, China.
Sadanandan E VeluChina National Institutes for Food and Drug Control, Beijing 100035, China.
Wei WangKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China; China Pharmaceutical University, Nanjing 210009, China. Electronic address: wwei.wang@ttuhsc.edu.
Ruiwen ZhangKey Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China; China Pharmaceutical University, Nanjing 210009, China. Electronic address: ruiwen.zhang@ttuhsc.edu.

Funding

UAB Center for Clinical and Translational Science (CCTS)UL1TR001417 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2015 to 2018
$31.4M
UAB CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCE (CCTS) UL1: BPCAUL1RR025777 · NCRR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUAY-WOODFORD, LISA MARIE · 2008 to 2011
$22.3M
Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer TherapyR01CA186662 · NCI · UNIVERSITY OF HOUSTON · PI ZHANG, RUIWEN · 2014 to 2018
$2.4M
Dietary Chemopreventive Components/Oncogene Interaction and CancerR01CA121211 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHANG, RUIWEN · 2007 to 2011
$1.4M
MDM2 AS A NEGATIVE REGULATOR OF P21 WAF1/CIP1R01CA112029 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHANG, RUIWEN · 2005 to 2009
$1.3M
NCATS NIH HHS UL1 TR001417NCI NIH HHS R01 CA112029NCI NIH HHS R01 CA121211NCI NIH HHS R01 CA186662NCRR NIH HHS 1UL1RR025777NCRR NIH HHS UL1 RR025777
6 · The paper itself

Abstract

We have recently designed and synthesized several novel iminoquinone anticancer agents that have entered preclinical development for the treatment of human cancers. Herein we developed and validated a quantitative HPLC-MS/MS analytical method for one of the lead novel anticancer makaluvamine analog, TCBA-TPQ, and conducted a pharmacokinetic study in laboratory rats. Our results indicated that the HPLC-MS/MS method was precise, accurate, and specific. Using this method, we carried out in vitro and in vivo evaluations of the pharmacological properties of TCBA-TPQ and plasma pharmacokinetics in rats. Our results provide a basis for future preclinical and clinical development of this promising anticancer marine analog.

Indexed as

AnimalsAntineoplastic AgentsChromatography, High Pressure LiquidPyrrolesQuinolonesRats, Sprague-DawleyTandem Mass Spectrometry7-(benzylamino)-1,3,4,8-tetrahydropyrrolo(4,3,2-de)quinolin-8(1H)-oneAntineoplastic AgentsPyrrolesQuinolonesLC-MS/MSMakaluvamine analogsPharmacokineticsRat plasmaTCBA-TPQ

Identifiers

PMID26233847
PMCPMC4716806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.